LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Liposomes Expand Cancer Drug's Bioavailability and Potency in Mouse Model

By LabMedica International staff writers
Posted on 16 May 2013
Print article
Image: First author Dr. Carey Anders (Photo courtesy of the University of North Carolina, Lineberger Comprehensive Cancer Center).
Image: First author Dr. Carey Anders (Photo courtesy of the University of North Carolina, Lineberger Comprehensive Cancer Center).
Encapsulation of the anticancer drug doxorubicin (doxo) within PEGylated liposomes increased the compound's intracranial tumor bioavailability, extended its lifetime in circulation, and improved the survival rate of mice bearing intercranial triple negative breast tumors.

Investigators at the University of North Carolina (Chapel Hill, USA) sought to decrease the toxicity of doxo and increase the length of time it could circulate in the blood by enclosing the drug within PEGylated liposomes.

The investigators inoculated athymic mice intracerebrally with triple negative breast cancer cells that expressed the enzyme luciferase. They then treated some of the animals with doxo ecapslulated in PEGylated liposomes (PLD) or with free doxo (NonL-doxo). Efficacy of the treatment was assessed by survival of the animals and detection of bioluminescence.

Results published in the May 1, 2013, issue of the journal PLOS ONE revealed that treatment with PLD resulted in a 1,500-fold higher plasma and 20-fold higher intracranial tumor bioavailability compared with NonL-doxo. In addition, PLD was detected in plasma and intracranial tumors 96 hours following treatment compared to the drug being undetectable in plasma and tumors after 24 hours in the NonL-doxo animals. Survival rates for the PLD treated mice were significantly prolonged as compared NonL-doxo.

Related Links:

University of North Carolina

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more